Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 2Colorectal Neoplasms 2Uveal Melanoma 1Rare Tumor 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1

Interventions

pembrolizumab 47Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 15Paclitaxel 14Cyclophosphamide 13Cisplatin 13Carboplatin 13Bevacizumab 12Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Leucovorin 10Irinotecan 10Fluorouracil 10Capecitabine 10trastuzumab deruxtecan 8fludarabine 8Pemetrexed 8Doxorubicin 8Cetuximab 8cemiplimab 7abemaciclib 7Trastuzumab 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × Crizotinib × Clear all
NCT04693468 2026-03-13

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

M.D. Anderson Cancer Center

Phase 1 Recruiting
111 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡